| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiova...
Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies ...
Canaccord Genuity analyst Edward Nash maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $12 to $20.
HC Wainwright & Co. analyst Ed Arce reiterates Inventiva (NASDAQ:IVA) with a Buy and maintains $22 price target.
Key financial results for the full year of 2023As of December 31, 2023, the Company's cash and cash equivalents amounted to...
HC Wainwright & Co. analyst Ed Arce reiterates Inventiva (NASDAQ:IVA) with a Buy and maintains $22 price target.
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lan...
Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral s...
HC Wainwright & Co. analyst Ed Arce maintains Inventiva (NASDAQ:IVA) with a Buy and announces $22 price target.
